Copyright
©The Author(s) 2022.
World J Hepatol. Jul 27, 2022; 14(7): 1269-1276
Published online Jul 27, 2022. doi: 10.4254/wjh.v14.i7.1269
Published online Jul 27, 2022. doi: 10.4254/wjh.v14.i7.1269
Figure 1 Pathological changes of drug-induced liver injury -induced by atezolizumab used for treatment of hepatocellular carcinoma (H&E 40×).
A: Portal inflammation and interfase hepatitis; B: Focal lobular necrosis; C: Frequent lobular acidophilic bodies; D: Ductal damage and migration of inflammatory cells into ductal epithelium; E: Hepatocyte rosettes as a result of liver regeneration; F: Hepatocanalicular cholestasis and biliary plugs.
- Citation: Bessone F, Bjornsson ES. Checkpoint inhibitor-induced hepatotoxicity: Role of liver biopsy and management approach. World J Hepatol 2022; 14(7): 1269-1276
- URL: https://www.wjgnet.com/1948-5182/full/v14/i7/1269.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i7.1269